88 results on '"Aerts, Joachim G.J.V."'
Search Results
2. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
3. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction
4. Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989–2020
5. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands
6. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study
7. Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers
8. Detection of Bacterial Colonization in Lung Transplant Recipients Using an Electronic Nose
9. The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
10. Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition
11. Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer.
12. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
13. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
14. Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease
15. Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC
16. Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application
17. Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations
18. Anti–Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
19. Acute COVID-19 treatment is not associated with health problems 2 years after hospitalization
20. Treatment Satisfaction of Patients With Advanced Non–Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL)
21. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
22. Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.
23. A new quantification method for assessing plasma concentrations of pemetrexed and its polyglutamate metabolites
24. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
25. High and individually variable enzymatic activity precludes accurate determination of pemetrexed, methotrexate and their polyglutamate metabolite concentrations in plasma
26. Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC.
27. Characterization of Mediastinal Lymph Node Physiology In Vivo by Optical Spectroscopy during Endoscopic Ultrasound-Guided Fine Needle Aspiration
28. Optical Spectroscopy for the Classification of Malignant Lesions of the Bronchial Tree
29. Impact of Centralization of Care for Malignant Peritoneal Mesothelioma: A historical cohort study from two Dutch expert centers
30. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy
31. Preoperative mediastinal staging in patients with cT1‐3NxM0 non‐small cell lung cancer.
32. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
33. Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non–Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results.
34. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
35. Reply to K. Masuda et al.
36. Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.
37. Iron deficiency anemia as initial presentation of a non-small cell lung carcinoma: A case report
38. Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma.
39. History of tuberculosis as an independent prognostic factor for lung cancer survival
40. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma
41. Follow-up strategy and survival for five common cancers: A meta-analysis.
42. Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients.
43. Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.
44. Diagnostic performance of electronic nose technology in chronic lung allograft dysfunction.
45. Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
46. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
47. A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands.
48. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy.
49. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
50. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.